Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
36
AMLX Quote, Financials, Valuation and Earnings
Last price:
$11.99
Seasonality move
:
-35.89%
Day range:
$10.88 - $11.42
52-week range:
$2.60 - $16.96
Dividend yield:
0%
P/E ratio:
21.03x
P/S ratio:
7.31x
P/B ratio:
3.76x
Volume:
2.1M
Avg. volume:
1.5M
1-year change:
190.31%
Market cap:
$1.2B
Revenue:
$87.4M
EPS (TTM):
-$1.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
-- | -$0.35 | -100% | -36.24% | $20.22 |
|
AVTR
Avantor, Inc.
|
$1.6B | $0.22 | -2.99% | -70.55% | $13.32 |
|
BAX
Baxter International, Inc.
|
$2.8B | $0.53 | 2.57% | 118.69% | $23.67 |
|
HUM
Humana, Inc.
|
$32.1B | -$3.99 | 10.38% | 3.4% | $287.25 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
TMCI
Treace Medical Concepts, Inc.
|
$61.8M | -$0.14 | -10.11% | -1650% | $5.27 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
$11.38 | $20.22 | $1.2B | 21.03x | $0.00 | 0% | 7.31x |
|
AVTR
Avantor, Inc.
|
$12.27 | $13.32 | $8.4B | 10.97x | $0.00 | 0% | 1.27x |
|
BAX
Baxter International, Inc.
|
$20.55 | $23.67 | $10.6B | 167.20x | $0.01 | 2.53% | 0.96x |
|
HUM
Humana, Inc.
|
$279.84 | $287.25 | $33.7B | 26.23x | $0.89 | 1.27% | 0.27x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$7.39 | $0.85 | $931.2M | 12.41x | $0.80 | 0% | 14.36x |
|
TMCI
Treace Medical Concepts, Inc.
|
$2.92 | $5.27 | $186.1M | -- | $0.00 | 0% | 0.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
1.76% | 1.060 | 0.4% | 13.34x |
|
AVTR
Avantor, Inc.
|
40.92% | 1.212 | 45.33% | 0.90x |
|
BAX
Baxter International, Inc.
|
57.29% | -0.374 | 83.18% | 0.96x |
|
HUM
Humana, Inc.
|
40.5% | 0.178 | 40.21% | 0.00x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
TMCI
Treace Medical Concepts, Inc.
|
44.1% | 1.352 | 16.46% | 2.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
-$120K | -$36M | -69.11% | -70.27% | 6113.38% | -$30.4M |
|
AVTR
Avantor, Inc.
|
$526.5M | $138.4M | -0.81% | -1.4% | 8.52% | $171.7M |
|
BAX
Baxter International, Inc.
|
$938M | $194M | -1.9% | -4.83% | 6.84% | $126M |
|
HUM
Humana, Inc.
|
-- | $400M | 4.25% | 7.3% | 0.41% | $836M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
TMCI
Treace Medical Concepts, Inc.
|
$39.7M | -$15.7M | -29.15% | -49.13% | -31.22% | -$11.9M |
Amylyx Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AMLX or AVTR?
Avantor, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -43.84%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Avantor, Inc.'s return on equity of -1.4%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M AVTRAvantor, Inc.32.42% -$1.04 $9.4B -
What do Analysts Say About AMLX or AVTR?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 77.7%. On the other hand Avantor, Inc. has an analysts' consensus of $13.32 which suggests that it could grow by 8.57%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than Avantor, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than Avantor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 AVTRAvantor, Inc.4 13 1 -
Is AMLX or AVTR More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.414%.
-
Which is a Better Dividend Stock AMLX or AVTR?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or AVTR?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 1.27x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M AVTRAvantor, Inc.1.27x 10.97x $1.6B -$711.8M
-
Which has Higher Returns AMLX or BAX?
Baxter International, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -1.8%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Baxter International, Inc.'s return on equity of -4.83%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M BAXBaxter International, Inc.33.09% $0.02 $16.9B -
What do Analysts Say About AMLX or BAX?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 77.7%. On the other hand Baxter International, Inc. has an analysts' consensus of $23.67 which suggests that it could grow by 15.17%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than Baxter International, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than Baxter International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 BAXBaxter International, Inc.2 13 1 -
Is AMLX or BAX More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.626%.
-
Which is a Better Dividend Stock AMLX or BAX?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.53% to investors and pays a quarterly dividend of $0.01 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or BAX?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Baxter International, Inc. quarterly revenues of $2.8B. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is higher than Baxter International, Inc.'s net income of -$51M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 0.96x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M BAXBaxter International, Inc.0.96x 167.20x $2.8B -$51M
-
Which has Higher Returns AMLX or HUM?
Humana, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of 0.59%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Humana, Inc.'s return on equity of 7.3%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M HUMHumana, Inc.-- $1.62 $31.2B -
What do Analysts Say About AMLX or HUM?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 77.7%. On the other hand Humana, Inc. has an analysts' consensus of $287.25 which suggests that it could grow by 2.65%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than Humana, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than Humana, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 HUMHumana, Inc.7 16 1 -
Is AMLX or HUM More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.811%.
-
Which is a Better Dividend Stock AMLX or HUM?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.27% to investors and pays a quarterly dividend of $0.89 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 35.45% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AMLX or HUM?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Humana, Inc. quarterly revenues of $32.6B. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is lower than Humana, Inc.'s net income of $194M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Humana, Inc.'s PE ratio is 26.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 0.27x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M HUMHumana, Inc.0.27x 26.23x $32.6B $194M
-
Which has Higher Returns AMLX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -255.85%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About AMLX or NBY?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 77.7%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -88.5%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is AMLX or NBY More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock AMLX or NBY?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or NBY?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 12.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 14.36x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M NBYNovaBay Pharmaceuticals, Inc.14.36x 12.41x $521K -$1.3M
-
Which has Higher Returns AMLX or TMCI?
Treace Medical Concepts, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -32.44%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Treace Medical Concepts, Inc.'s return on equity of -49.13%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M -
What do Analysts Say About AMLX or TMCI?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 77.7%. On the other hand Treace Medical Concepts, Inc. has an analysts' consensus of $5.27 which suggests that it could grow by 80.48%. Given that Treace Medical Concepts, Inc. has higher upside potential than Amylyx Pharmaceuticals, Inc., analysts believe Treace Medical Concepts, Inc. is more attractive than Amylyx Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 TMCITreace Medical Concepts, Inc.1 4 0 -
Is AMLX or TMCI More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AMLX or TMCI?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Treace Medical Concepts, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or TMCI?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Treace Medical Concepts, Inc. quarterly revenues of $50.2M. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is lower than Treace Medical Concepts, Inc.'s net income of -$16.3M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Treace Medical Concepts, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 0.84x for Treace Medical Concepts, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M TMCITreace Medical Concepts, Inc.0.84x -- $50.2M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
